Article
Polylactic Acid and Polycaprolactone Blended Cosmetic Microneedle for Transdermal Hispidin Delivery System

Seungyeon Lee 1,†, Jihye Lee 2,†, Kanghyun Choi 2,†, Hyoseon Kim 2, Youngkum Park 2,*, Juhee Yoon 3, June Hyun Kim 4,* and Seongwoo Ryu 1,*

1 Department of Materials Science and Engineering, The University of Suwon, 17 Wauan-gil, Bongdam-eup, Hwaseong-si 18323, Gyeonggi-do, Korea; sygm09@naver.com
2 Gragem Co., Ltd., Incheon 21999, Korea; poster35@gragem.com (J.L.); hyuny24k@gragem.com (K.C.); sunny77sun@gragem.com (H.K.)
3 Department of Polymer Science and Engineering, Inha University, Incheon 402-751, Korea; yoonjb0803@naver.com
4 Department of Biotechnology, The University of Suwon, 17 Wauan-gil, Bongdam-eup, Hwaseong-si 18323, Gyeonggi-do, Korea
* Correspondence: ykumpark@gragem.com (Y.P.); jk8199@snuwon.ac.kr (J.K.); ryu@snuwon.ac.kr (S.R.);
† All authors contributed equally to this work.

Abstract: Microneedles (MNs) are a new system of effective drug delivery that create micron-sized pathways to the epidermis or upper dermis regions of the skin. In this study, we developed coated-type microneedles for direct hispidin delivery to the skin. Hispidin is a well-known plant-derived antioxidant component showing antitumor, anti-inflammatory, antiallergic, antiangiogenic, antioxidant, hypoglycemic, hypolipidemic, and immunomodulatory activities. Polymeric blends of polylactic acid (PLA) and polycaprolactone (PCL) were casted as MNs to enhance skin permeability. PLA/PCL MNs exhibited the highest strength of 51.26 MPa with a width of ~200 μm. Hispidin was directly coated onto the MNs with PLA/PCL blends to form delivery layers. Compared to the hispidin-only delivery layer, skin permeability of hispidin increased by over 50% when using agarose gel in in vitro tests. In a dose-dependent manner, hispidin coated on PLA/PCL MNs also showed a brightening effect, as well as anti-inflammatory activity at the gene and protein level in skin cell culture experiments. It also demonstrated antimicrobial activity, and showed no cytotoxicity to skin cells. These results suggest that the PLA/PCL MN system with hispidin may have great potential as a prototype platform for various drug delivery systems, allowing the development of more effective subcutaneous delivery of vaccines, oligonucleotides, insulin, and many other cosmetic applications.

Keywords: microneedles; hispidin; drug delivery

1. Introduction

Compared to topical and transdermal delivery systems, microneedles (MNs) have advantages for delivering drugs through the transdermal route [1,2]. The stratum corneum layer is a major barrier for delivering drugs, allowing only limited, low-molecular-weight drugs to pass through it [3,4]. MNs are micron-sized needles that allow hydrophilic high-molecular-weight compounds to pass through the stratum corneum, allowing drug molecules to enter the skin [5–7]. Recently, different types of MNs have been investigated, including coated, solid, hollow, and hydrogel systems. The major purpose of MNs is to deliver drugs into the epidermis via pathways created by MNs [8–11].

Hispidin (4-O-β-D-glucopyranoside) is a yellowish natural substance present in Phellinus linteus, which can be synthesized using a general method. Its structural features are similar to aromatic compounds such as α-tocopherol and other phenolic antioxidants, exhibiting a double bond with a benzene ring. Hispidin, a polyphenol compound isolated from Phellinus linteus, has been reported to possess antioxidant activity [12]. Its antioxidant
activity is about 3–5 times that of water-soluble vitamin E, equivalent to the reported value for beta hydroxy acid (BHA). Recently, it was also demonstrated that hispidin can inhibit the macrophage-mediated inflammatory response by downregulating nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activations [13]. Hispidin also inhibits palmitate-induced nuclear condensation in mouse myoblast cell line (C2C12) [14]. Hispidin is effective due to its anti-p21 activated kinase 1 (PAK1) activity. As expected, PAK1 silencing clearly reduced the melanogenic activity of this cell line by around 50%, proving that PAK1 is essential for alpha-melanocyte stimulating hormone (MSH)-induced melanogenesis [15]. In a prior study, aimed at identifying active oxygen degradation and whitening effects, 1, 2, and 5 µM concentrations of hispidin were confirmed to decrease melanin production. Hispidin, a polyphenolic substance, identified as 6-(3,4-dihydroxystyryl)-4-hydroxy-2-pyranone by Edwards in 1961, was first isolated from the fruiting body of I. hispidus by Zopf (1889) [16]. It has also been reported that hispidin has anticancer, antibacterial, and hypoglycemic regulatory functions [16–19]. Recently, Hong Jun Shao et al. demonstrated that hispidin can inhibit the macrophage-mediated inflammatory response by downregulating NF-κB activation [20]. Therefore, hispidin itself is also a raw material that can be used in cosmetics. It has a superior effect compared to the existing method of absorbing raw materials through the skin by increasing the skin permeability using a micro epidermal delivery system. Antibacterial patches, whitening patches, wrinkle improvement patches, etc. can be applied using this.

However, the effects of hispidin on lipopolysaccharide (LPS)-induced macrophage reactive oxygen species (ROS) levels, phagocytosis, and cytokine production, as well as its molecular signaling mechanisms, remain unclear [13]. Herein, we developed a polylactic acid (PLA) and polycaprolactone (PCL) MN drug delivery system for hispidin. PLA and PCL were blended for high strength and effective skin permeability. On the casted PLA/PCL layer, a delivery layer was coated with PLA/PCL and hispidin. Blended PLA and PCL were optimized and compared with single-layer-coated hispidin; the skin permeability of the composite delivery PLA/PCL layer was measured. It was confirmed that no single or mixed substance was cytotoxic. Then, when we checked the whitening effect at the optimal concentration, we found that melanin production decreased as the concentration increased. We observed the anti-inflammatory properties of PLA, PCL, and hispidin on LPS-induced RAW264.7 macrophage cells. Our results showed that PLA, PCL, and hispidin treatment significantly reduced the production of cellular nitric oxide (NO), as well as inflammatory gene RNA and protein, in a dose-dependent manner. The antimicrobial activity of hispidin was measured using the paper disc method.

2. Materials and Methods

2.1. Materials

Arbutin (Sigma Aldrich, St. Louis, MO, USA), alpha-melanocyte-stimulating hormone, Sigma Aldrich (α-MSH, St. Louis, MO, USA), polycaprolactone (PCL, Sigma Aldrich, St. Louis, MO, USA), polylactic acid (PLA, Sigma Aldrich, St. Louis, MO, USA), dimethyl sulfoxide (DMSO, Sigma Aldrich, St. Louis, MO, USA), hispidin (TCI, Tokyo, Japan), B16F10 (Korean Cell Line Bank, Seoul, Korea), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Biomax, Seoul, Korea), and a cell proliferation assay kit (Biomax, Seoul, Korea) were used as received.

2.2. Fabrication of MNs

PLA/PCL blends were prepared for the tensile strength and stability tests. PLA/PCL (100:0, 90:10, 80:20, 70:30 wt.%) (5 g) was solubilized at 180 °C on a hot plate. After it completely melted, the mixture was poured immediately into a sampling mold and cooled at room temperature for 2 days. Hispidin, PLA, and PCL were coated on the 12 mm diameter MNs by a spin-coating process. For fabrication of coated MNs with hispidin, hispidin (2 mg) was mixed with deionized water (DIW) (10 mL) until completely melted. A
150 μL solution was raised on the center of the MNs and subject to a spin-coating process (increasing from zero to 3000 rpm for 10 s; increasing one more time to 5000 rpm for 10 s; maintaining for 10 s; decreasing for 10 s). The coated MNs were dried for 24 h at room temperature. For fabrication of coated MNs with hispidin, PLA (0.08 mg) and PCL (0.02 mg) were dissolved in DMSO (2.8 mL). Then, the temperature was raised to 100 °C for 24 h in a water bath. The solution was double-boiled in a water bath at 100 °C for 24 h. After the melting process, the mixed hispidin (2 mg) was melted with the PLA/PCL blended polymer. A 100 μL solution was raised on the center of the MNs and subjected to a spin-coating process (increasing from zero to 700 rpm for 30 s; maintaining for 10 s; decreasing for 10 s). The coated MNs were dried for 24 h at room temperature.

2.3. Characterization
Mechanical properties and microstructure of MNs: The material characterization of PLA/PCL was performed using various material analyses. Tensile strength was measured using a Universal Testing Machine (LR10K Plus, LLOYD, Steyning way, BR, UK). For tensile tests, PLA/PCL blends were poured into the sampling molds and cooled for 48 h. To determine the best properties, fabricated samples were stretched at room temperature to determine the maximum strain until fracture. After extensive tests, we obtained the stress–strain curve of each sample. Scanning electron microscopy (SEM, APREO, FEI, Hillsboro, OR, USA) was used to confirm the suitability of the coating process. We also measured the thickness of the materials by analyzing the cross-sectional area of coated MNs.

Hispidin delivery test: We estimated the absorbance using Ultraviolet-Visible-Near Infrared (UV–Vis–NIR) spectrophotometry (Lambda 750, Perkin Elmer, Waltham, MA, USA). The characteristic peak of hispidin was measured by estimating a standard curve. We estimated the absorbance of each concentration (0.12, 0.1, 0.08, 0.06, 0.04, and 0.02 wt.%) of hispidin and constructed a standard curve of hispidin. Agarose gel was used to measure the permeability of hispidin into the skin. Agarose gel is a homogeneous and semi-clear substance which mimics porcine skin for skin transitional substances [21]. The coated MNs were applied to the agarose gel (3 g) for 5 min with hand pressure. After MNs were removed, agarose gel was dissolved into DMSO (111 mL). The amount of hispidin in DMSO was measured by UV–Vis, and the permeability of hispidin was estimated using a standard curve by comparing with a coated amount of pristine hispidin.

Cell Culture and Viability: B16F10 melanoma cells and Raw 264.7 murine macrophage cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (GIBCO Thermo Fisher Scientific, Waltham, MA, USA). Cells were cultured in a 5% CO2 incubator maintained at 37 °C. An MTT assay was used to ascertain the cytotoxicity of the three mixed components. B16F10 melanoma cells were dispensed into a 96-well plate at a cell number of 1 × 10^4 per well; the samples were added by concentration and incubated in a CO2 incubator at 37 °C for 24 h. RAW264.7 macrophage cells were seeded into 96-well plates at a concentration of 5 × 10^6 cells per well, with different concentrations (0 μg/mL to 50 μg/mL) of hispidin, PLA, and PCL (10 to 10,000 ppm) and treated for 24 h. Subsequently, a solution of 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Quanti-Max TM, Biomax, Seoul, Korea) was added to each well and then incubated in an incubator (37 °C, 5% CO2) for 4 h. A UV MAX kinetic microplate reader (Synergy MT microplate reader, BioTek, Winooski, USA) was used to measure the absorbance at 450 nm. The experiment was conducted three times under the same conditions.

NO Production and Melanin Content Assay: The RAW264.7 cells were treated with hispidin, PLA, and PCL, as well as stimulation with LPS (lipopolysaccharide, Sigma Aldrich, St. Louis, MO, USA). NO generation was determined using Griess reagent (nitric oxide plus detection kit, Intron Biotechnology, Gyeonggi-do, Korea), with nitrite production measured according to the absorbance at 540 nm.

Melanin Content Assay: B16F10 melanoma cells were dispensed into a six-well plate at 2 mL and incubated for 48 h in DMEM solution containing 10% FBS. Then, 50 nM of
α-MSH was added and incubated for 72 h at 37 °C. One day earlier, the samples were incubated for 24 h at 37 °C at each concentration. After the incubation was completed, 1 N NaOH and 10% DMSO were added to the cell pellet obtained by centrifugation at 13,000 rpm for 5 min; samples were boiled at 95 °C for 20 min, completely dissolving the melanin, and 150 µL samples were transferred to a 96-well plate, followed by microplate reader measurement of the absorbance at 490 nm. The same conditions were repeated three times to obtain an average value and calculate the amount of melanin produced in each well.

Isolation of Total RNA and RT-PCR: Total RNA was isolated with an RNeasy Mini kit (RNeasy Mini kit, Qiagen, Hilden, USA). RNA was reverse-transcribed with an oligo (dT) primer using the Super Script First-Strand Synthesis System (Intron power complementary DNA (cDNA) synthesis kit, Intron Biotechnology, Korea). RT-PCR was performed using Recombinant Taq DNA polymerase, according to the manufacturer’s instructions (2× PCR master mix solution, Intron, Gyeonggi-do, Korea). The glyceraldehyde 3-phosphate dehydrogenase (GAPDH) messenger RNA (mRNA) level was used as a control. The following primers were used: iNOS forward 5′–GCAGAATGTGACCATCATGG–3′ and reverse 5′–ACAACCTTGGTGTTGAAGGC–3′; COX-2 forward 5′–CCACCTCAGGGATCTGGA–3′ and reverse 5′–AGTCATCTGCTACGGGAGGA–3′; GAPDH forward 5′–ACACAGTCCA TGCCATACAC–3′ and reverse 5′–CACCCACCTTGTTGCTGTAGCC–3′. The conditions for PCR were as follows: 30 cycles of 94 °C denaturation for 30 s, 60 °C annealing for 30 s, and 72 °C extension for 30 s. The PCR products were analyzed by electrophoresis on 2% agarose gels stained with Red safe nucleic acid staining solution (Intron).

Western Blotting: Cell extracts were resolved by SDS/PAGE (BR456-1043, Bio Rad, Korea), transferred to a PVDF membrane (BR162-0177, Bio Rad, Seoul, Korea), and immunoblotted with anti-iNOS (#2977S, Cell Signaling, Massachusetts, USA), anti-COX-2 (#12282S, Cell Signaling, USA), or anti-β-Actin (Ab8227, Abcam, MA, USA) antibodies. Reactive bands were detected by chemiluminescence using Clarity™ Western enhanced chemiluminescence (ECL) Substrate (BR170-5060, Bio Rad, Seoul, Korea).

Strains: For the Staphylococcus aureus (Korea Collection for Type Cultures; KCTC 1916), Staphylococcus epidermidis (KCTC 1917), and Pseudomonas aeruginosa (KCTC 2153) experiments, strains from the Korea Cell Line Bank were used. After adding them to the TSA (Tryptic Soy Agar) medium, the culture was enriched for 18 to 24 h at 35 to 37 °C. In addition, for Escherichia coli (KCTC 1039), a strain from the same institution was used. After adding it to TSB (Tryptic Soy Broth) medium, the optical density (OD) value (600 nm) was fixed in a range of 0.760 to 0.802 for 18 to 24 h at 35 to 37 °C using the method previously described (Table 1).

### Table 1. Antibacterial activity according to paper disc method.

| Treatments | Con. (µM) | Size of Clear Zone (mm) |
|------------|----------|------------------------|
|            |          | Staphylococcus epidermidis | Escherichia coli | Pseudomonas aeruginosa | Staphylococcus aureus |
| Hispidin    | 20       | 0.5                    | 0.4             | 0.5                  | 0.4                  |
| Hispidin    | 10       | 0.4                    | 0.4             | 0.4                  | -                    |
| Hispidin    | 5        | -                      | -               | -                    | -                    |
| Hispidin    | 1        | -                      | -               | -                    | -                    |
| 70% EtOH (1) | -       | 0.6                    | 0.6             | 0.6                  | 0.6                  |
| Sterilized DW (2) | - | -                      | -               | -                    | -                    |

(1) Positive control; (2) Negative control.

Measurement of Antibacterial Activity Using Paper Disc Method: The antimicrobial efficacy of each substance was measured using the paper disc method according to Murray [22]. The strain in the main culture was determined by increasing the activity under the optimal culture conditions and then incubating TSB (Tryptic Soy Broth) for about 6 h in the optimal medium to fix the OD value of the culture solution at 0.8. Then, 100 µL of the culture medium of each strain was evenly spread on the optimal medium in TSA (Tryptic Soy Agar); the used concentrations of hispidin were 1, 5, 10, and 20 µM/disc. A sterilized paper disc (Whatman No. 5 paper, Sigma-Aldrich, St. Louis, MO, USA) was
used after absorbing and drying the sample under aseptic conditions; samples were then
cultured for 24 h at the optimum culture temperature of each strain, and each fraction with
the diameter of the clear zone (mm) was created around the disc. The antibacterial activity
was measured, and the experiment was repeated three times to produce an average value.

Statistical Analysis: All data were analyzed using one-way ANOVA for normally
distributed values. Statistical significance was determined using one-way analysis of
variance followed by the Tukey–Kramer multiple comparisons post hoc test to analyze
differences between groups. Statistical analyses were performed using PRISM software
(GraphPad Software, San Diego, CA, USA).

3. Results and Discussion
3.1. Microstructure and Mechanical Strength of MNs

We fabricated MNs by blending PLA/PCL via the direct casting and spin-coating
method (Figure 1a). The MN structure was casted as a pyramid-shaped tetrahedral structure
for the transdermal delivery system. Each needle had a length of 200 µm and width of
200 µm (Figure 1b). Previously, pyramid shapes with widths and heights in the range of
250 µm were found to exhibit effective permeability for drug delivery systems. Particularly
for transdermal drug delivery (TDD), among various types of MNs, pyramid-shaped MNs
can transfer drugs efficiently into the skin [23]. Furthermore, for effective drug delivery into
the epidermis, we measured the tensile properties of various PLA/PCL blended structures
(Figure 1c). The tensile strength of each blended PLA/PCL sample had values of 43.76 MPa
at 100:0 wt.%, 35.42 MPa at 90:10 wt.%, 51.26 MPa at 80:20 wt.%, and 35.29 MPa at 70:30 wt.%.
The highest ultimate strength was observed when PLA:PCL was blended at 80:20 wt.%
with a Young’s modulus of 13.7 GPa. Therefore, effective physical drug delivery properties
were expected to be found for the 80:20 wt.% blend of PLA/PCL. On this MN structure,
a coated type of transdermal hispidin delivery system was fabricated. For comparison,
two different coated systems were developed. For the first system, dissolved hispidin
solution was directly coated onto the MNs surface (Figure 1d). For another system, hispidin
dissolved in PLA/PCL blended solution was coated onto the MNs surface (Figure 1e). Both
samples showed sharp tetragonal MN structures even after a coating of 0.156 µm–0.372
µm on each delivery layer.

3.2. Hispidin Delivery Test

To observe the delivery effects due to MN skin permeability, we replicated the system
using in vitro agarose gels. The amounts of hispidin delivered to the agarose gel were
calculated using UV–Vis calibration standard curves. The pristine hispidin showed the
highest absorbance at a wavelength of 358 nm, and we estimated the absorbance of each
concentration (0.12, 0.1, 0.08, 0.06, 0.04, and 0.02 wt.% of hispidin) (Figure 2a). For the
delivery layers, amounts of PLA and PCL were also calculated using UV–Vis calibration
standard curves at 282 nm and 290 nm (Figure 2b,c). After applying MNs to agarose gel (3 g)
for 5 min, the amounts of delivered hispidin were observed. Compared to hispidin-only
delivery layers, hispidin with PLA/PCL blended polymer delivery layers exhibited higher
absorption peaks at 358 nm (Figure 2d). According to the UV–Vis calibration standard
curves, 0.03 mg of hispidin was contained on the MN surface and 0.0036 mg (12.13%) was
delivered from the coated MNs to the agarose gel. When we developed delivery layers
with PLA/PCL blends, the delivered hispidin increased to 18.36%. This result indicates
that the high-strength biodegradable polymer offers an effective physical drug delivery
system for hispidin and many other related molecules.
**Figure 1.** Microstructure and mechanical strength of microneedles (MNs). (a) Fabrication process of MNs. (b) SEM image of casted pristine polylactic acid (PLA)/polycaprolactone (PCL) MNs. (c) Stress–strain graph of various PLA/PCL blended structures. (d) SEM image of MNs after coating of hispidin delivery layer. (e) SEM image of MNs after coating of hispidin with PLA/PCL blended polymer delivery layer.
3.2. Hispidin Delivery Test
To observe the delivery effects due to MN skin permeability, we replicated the system using in vitro agarose gels. The amounts of hispidin delivered to the agarose gel were calculated using UV–Vis calibration standard curves. The pristine hispidin showed the highest absorbance at a wavelength of 358 nm, and we estimated the absorbance of each concentration (0.12, 0.1, 0.08, 0.06, 0.04, and 0.02 wt.% of hispidin) (Figure 2a). For the delivery layers, amounts of PLA and PCL were also calculated using UV–Vis calibration standard curves at 282 nm and 290 nm (Figure 2b,c). After applying MNs to agarose gel (3 g) for 5 min, the amounts of delivered hispidin were observed. Compared to hispidin-only delivery layers, hispidin with PLA/PCL blended polymer delivery layers exhibited higher absorption peaks at 358 nm (Figure 2d). According to the UV–Vis calibration standard curves, 0.03 mg of hispidin was contained on the MN surface and 0.0036 mg (12.13%) was delivered from the coated MNs to the agarose gel. When we developed delivery layers with PLA/PCL blends, the delivered hispidin increased to 18.36%. This result indicates that the high-strength biodegradable polymer offers an effective physical drug delivery system for hispidin and many other related molecules.

Figure 2. In vitro skin permeability of hispidin with PLA/PCL blended MNs. (a) Ultraviolet-Visible (UV–Vis) spectroscopy of hispidin, (b) PCL, (c) PLA, and (d) MN in vitro tested sample.

3.3. Cell Viability Test with Hispidin, PCL, PLA, and Mixture
The transdermal MN delivery system passed through the epidermis and underwent biodegradation. Once hispidin was eluted from the MNs as a solution, the effect of solution blends had a similar antibacterial activity. To determine the concentration of hispidin at which no cytotoxicity was present, B16F10 melanoma cells were treated with hispidin, PCL, and PLA in various concentrations for 24 h. The final concentration of DMSO used was less than 0.1%, which is a concentration that does not affect the cell viability. The MTT assays revealed that there were 103%, 95%, 91%, and 90% levels of viable B16F10 melanoma cells after treatment with hispidin at concentrations ranging from 1–20 µM (Figure 3a). PLA and PCL were dissolved in 1% DMSO for 24 h at 55 °C, giving concentrations of 10, 100, 1000, and 10,000 ppm for both materials used for the cell viability test. PLA at concentrations ranging from 10–10,000 ppm showed values of 101%, 98%, 91%, and 90% viability for B16F10 melanoma cells (Figure 3c). Furthermore, PCL at concentrations ranging from 10–10,000 ppm demonstrated values of 121%, 122%, 119%, and 120% viability for B16F10 melanoma cells (Figure 3b). Hispidin (1–20 µM) mixed with PLA/PCL at the same concentration (10,000 ppm) showed levels of 100–120% cell viability (Figure 3d). These results suggest that hispidin, PCL, and PLA, as well as their mixtures, exhibited almost identical cell viability compared to the control.
at which no cytotoxicity was present, B16F10 melanoma cells were treated with hispidin, PCL, and PLA in various concentrations for 24 h. The final concentration of DMSO used was less than 0.1%, which is a concentration that does not affect the cell viability. The MTT assays revealed that there were 103%, 95%, 91%, and 90% levels of viable B16F10 melanoma cells after treatment with hispidin at concentrations ranging from 1–20 µM (Figure 3a). PLA and PCL were dissolved in 1% DMSO for 24 h at 55 °C, giving concentrations of 10, 100, 1000, and 10,000 ppm for both materials used for the cell viability test. PLA at concentrations ranging from 10–10,000 ppm showed values of 101%, 98%, 91%, and 90% viability for B16F10 melanoma cells (Figure 3c). Furthermore, PCL at concentrations ranging from 10–10,000 ppm demonstrated values of 121%, 122%, 119%, and 120% viability for B16F10 melanoma cells (Figure 3b). Hispidin (1–20 µM) mixed with PCL/PLA at the same concentration (10,000 ppm) showed levels of 100–120% cell viability (Figure 3d). These results suggest that hispidin, PCL, and PLA, as well as their mixtures, exhibited almost identical cell viability compared to the control.

Figure 3. Cell viability test with hispidin, PCL, PLA, and their mixture in B16F10 melanoma cells. (a) B16F10 cells were treated with various concentrations (1–20 µM) of hispidin, (b) PCL (10–10,000 ppm), and (c) PLA (10–10,000 ppm) for 24 h. Cell survival was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (d) B16F10 cells were pretreated with hispidin (1–20 µM) mixed with PLA/PCL at identical concentrations (10,000 ppm). *p < 0.05, **p < 0.01 versus control.

3.4. Brightening Test with Hispidin, PCL, PLA, and Mixture

To investigate the effects of hispidin and mixtures of substances on the brightening effects using melanogenesis, the melanin contents of B16F10 melanoma cells were counted after treatment with hispidin and mixtures of the substances. α-MSH was used as a positive control and arbutin was used as a negative control. Hispidin at various concentrations in a range of 1–20 µM decreased melanin contents to 60%, 49%, 36%, and 30% in a dose-dependent manner (Figure 4a). Furthermore, 1 µM arbutin treatment decreased melanin content by 50% compared to α-MSH treatment. In addition, when the mixed substances were treated, melanin contents decreased to 76%, 63%, 52%, and 40% (Figure 4b). This shows that treatment with the mixed substances and hispidin significantly inhibited melanin content in a dose-dependent manner. These results suggest that hispidin, PCL, PLA, and their mixture may have powerful brightening effects.

3.5. Anti-Inflammatory Test

To determine whether hispidin, PLA, and PCL may have effects on macrophage cell viability, RAW264.7 macrophage cells were treated with hispidin at various concentrations (0, 1, 2.5, 5, 10, and 20 µM) and with PCL and PLA (10 to 10,000 ppm) for 24 h. Hispidin, PLA, and PCL showed no effects on macrophage cell viability (Figure 5a–c). To examine whether hispidin has anti-inflammatory activities, the nitric oxide (NO) levels in RAW264.7 macrophage cell supernatants were examined. The results showed that treatment with hispidin, PCL, and PLA could dose-dependently decrease the production of NO in LPS-treated RAW264.7 macrophage cells (Figure 5d). Furthermore, the expression levels of iNOS and COX-2 were tested according to RNA levels. Hispidin at 50 µM decreased iNOS RNA levels (Figure 5e). Furthermore, hispidin treatment at 50 µM significantly downregulated the LPS-induced iNOS protein expression (Figure 5f).
after treatment with hispidin and mixtures of the substances. α-MSH was used as a positive control and arbutin was used as a negative control. Hispidin at various concentrations in a range of 1–20 µM decreased melanin contents to 60%, 49%, 36%, and 30% in a dose-dependent manner (Figure 4a). Furthermore, 1 µM arbutin treatment decreased melanin content by 50% compared to α-MSH treatment. In addition, when the mixed substances were treated, melanin contents decreased to 76%, 63%, 52%, and 40% (Figure 4b). This shows that treatment with the mixed substances and hispidin significantly inhibited melanin content in a dose-dependent manner. These results suggest that hispidin, PCL, PLA, and their mixture may have powerful brightening effects.

Figure 4. Effects of hispidin and mixtures of substance on melanogenesis using B16F10 melanoma cells. (a) B16F10 cells were treated with various concentrations (1–20 µM) of hispidin. (b) B16F10 cells were pretreated with hispidin (1–20 µM) mixed with PLA/PCL at identical concentrations (10,000 ppm). ** p < 0.01 versus control.

3.5. Anti-Inflammatory Test

To determine whether hispidin, PLA, and PCL may have effects on macrophage cell viability, RAW264.7 macrophage cells were treated with hispidin at various concentrations (0, 1, 2.5, 5, 10, and 20 µM) and with PCL and PLA (10 to 10,000 ppm) for 24 h. Hispidin, PLA, and PCL showed no effects on macrophage cell viability (Figure 5a–c). To examine whether hispidin has anti-inflammatory activities, the nitric oxide (NO) levels in RAW264.7 macrophage cell supernatants were examined. The results showed that treatment with hispidin, PCL, and PLA could dose-dependently decrease the production of NO in LPS-treated RAW264.7 macrophage cells (Figure 5d). Furthermore, the expression levels of iNOS and COX-2 were tested according to RNA levels. Hispidin at 50 µM decreased iNOS RNA levels (Figure 5e). Furthermore, hispidin treatment at 50 µM significantly downregulated the LPS-induced iNOS protein expression (Figure 5f).

Figure 5. PLA, PCL, and hispidin inflammation in RAW264.7 cells. (a) Cells were treated with different concentrations of PLA, (b) PCL, and (c) hispidin with PLA/PCL, and incubated for 24 h. Cell viability was measured by MTT assay. (d) RAW264.7 cells were treated with indicated treatments. Levels of nitric oxide (NO) production were measured using Griess reagent. (e,f) The RNA and protein expression levels of inducible nitric oxide synthase (iNOS) and cytochrome c oxidase subunit II (COX-2) were detected by RT-PCR and Western blot testing, and the results were quantified. * p < 0.05, ** p < 0.01, *** p < 0.001 versus control.
3.6. Antibacterial Activity by Paper Disc Method

To measure the antimicrobial activity of hispidin, we used the paper disc method with several bacterial strains, namely, \textit{Staphylococcus epidermidis}, \textit{Escherichia coli}, \textit{Pseudomonas aeruginosa}, and \textit{Staphylococcus aureus}, as shown in Figure 6. The sizes of the clear zones for the paper disc method are shown in Figure 6; these clear zones were significantly observed from all strains (Table 1). \textit{Staphylococcus epidermidis}, \textit{Escherichia coli}, and \textit{Pseudomonas aeruginosa} showed antibacterial activities of 10 \(\mu\)M and 20 \(\mu\)M at a hispidin concentration of 0.4 mm and of 10 \(\mu\)M and 20 \(\mu\)M at a hispidin concentration of 0.5 mm, respectively (Table 1 and Figure 6). On the other hand, \textit{Staphylococcus aureus} produced a 0.4 mm spot at a concentration of 20 \(\mu\)M and showed antimicrobial activity at a concentration of 20 \(\mu\)M (Table 1 and Figure 6). This indicates that hispidin might have relatively more antibacterial activity in \textit{Staphylococcus epidermidis}, \textit{Escherichia coli}, and \textit{Pseudomonas aeruginosa} than in \textit{Staphylococcus aureus}. Overall, these results suggest that hispidin may have strong antibacterial activities toward the applied surfaces.

![Figure 6. Antibacterial activity determined by paper disc method. (a) \textit{Staphylococcus epidermidis}, (b) \textit{Escherichia coli}, (c) \textit{Pseudomonas aeruginosa}, and (d) \textit{Staphylococcus aureus}. Hispidin concentrations were 1 \(\mu\)M, 5 \(\mu\)M, 10 \(\mu\)M, and 20 \(\mu\)M. The positive control was obtained using 70% EtOH and the negative control was obtained using sterilized DIW.](image)

4. Conclusions

Hispidin with PLA/PCL blends showed a brightening effect with anti-inflammatory activity at the gene and protein levels in skin cell culture experiments. PLA/PCL was casted using MNs for enhancing skin permeability and exhibited the highest strength of 51.26 MPa for effective drug delivery. Compared to that of a hispidin-only delivery layer, the skin
permeability of hispidin increased by over 50% in agarose gel in vitro tests. Hispidin coated on PLA/PCL MNs also showed a brightening effect with anti-inflammatory activity at the gene and protein levels in skin cell culture experiments. The antimicrobial activity of hispidin coating was observed in a dose-dependent manner, without cytotoxicity to skin cells. We believe that PLA/PCL MN systems with hispidin have great potential as a prototype platform for various drug delivery systems, allowing more effective delivery of subcutaneous vaccines, oligonucleotides, insulin, and many other cosmetic applications.

Author Contributions: Conceptualization, Y.P., J.K. and S.R.; methodology, S.L., J.L. and K.C.; software, S.L.; validation, S.L., J.L. and K.C.; formal analysis, S.L., J.L., K.C. and J.Y.; investigation, S.L., J.L., K.C., H.K. and J.Y.; resources, Y.P., J.K. and S.R.; data curation, S.L., J.L. and K.C.; writing—original draft preparation, S.L., J.L. and K.C.; writing—review and editing, Y.P., J.K. and S.R.; visualization, S.L. and K.C.; supervision, S.R.; project administration, Y.P., J.K. and S.R.; funding acquisition, Y.P., J.K. and S.R.; All authors have read and agreed to the published version of the manuscript. S.L., J.L. and K.C. are equally contributed.

Funding: This work was supported by the Technology development Program (S2804396) funded by the Ministry of SMEs and Startups (MSS, Korea).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Prausnitz, M.R.; Langer, R. Transdermal drug delivery. Nat. Biotechnol. 2008, 26, 1261–1268. [CrossRef] [PubMed]
2. Gupta, M.; Agrawal, U.; Vyas, S.P. Nanocarrier-based topical drug delivery for the treatment of skin diseases. Expert Opin. Drug Deliv. 2012, 9, 783–804. [CrossRef] [PubMed]
3. Ita, K. Transdermal Delivery of Drugs with Microneedles-Potential and Challenges. Pharmaceutics 2015, 7, 90–105. [CrossRef] [PubMed]
4. Bora, P.; Kumar, L.; Bansal, A.K. Microneedle Technology for Advanced Drug Delivery: Evolving Vistas. CIRPS 2008, 9, 7–10.
5. Williams, A.C.; Barry, B.W. Penetration enhancers. Adv. Drug Deliv. Rev. 2004, 56, 603–618. [CrossRef] [PubMed]
6. Sharma, D. Microneedles: An Approach in Transdermal Drug Delivery: A Review. Pharma Tutor 2018, 6, 7–15. [CrossRef]
7. Akhtar, N. Microneedles: An Innovative Approach to Transdermal Delivery—A Review. Int. J. Pharm. Pharm. Sci. 2014, 8, 18–25.
8. Li, J.; Zeng, M.; Shan, H.; Tong, C. Microneedle Patches as Drug and Vaccine Delivery Platform. Curr. Med. Chem. 2017, 24, 2413–2422. [CrossRef] [PubMed]
9. Prausnitz, M.R. Engineering Microneedle Patches for Vaccination and Drug Delivery to Skin. Annu. Rev. Chem. Biomol. Eng. 2017, 8, 177–200. [CrossRef] [PubMed]
10. Suzuki, M.; Takahashi, T.; Aoyagi, S. 3D laser lithographic fabrication of hollow microneedle mimicking mosquitoes and its characterization. Int. J. Nanotechnol. 2018, 15, 157–173. [CrossRef]
11. Cheung, K.; Han, T.; Das, D.B. Effect of force of microneedle insertion on the permeability of insulin in skin. J. Diabetes Sci. Technol. 2014, 8, 444–452. [CrossRef] [PubMed]
12. Tu, P.T.B.; Chompoon, J.; Tawata, S. Hispidin and related herbal compounds from Alpinia zerumbet inhibit both PAK1-dependent melanogenesis in melanocytes and reactive oxygen species (ROS) production in adipocytes. Drug Discov. Ther. 2015, 9, 197–204.
13. Han, Y.H.; Chen, D.Q.; Jin, M.H.; Jin, Y.H.; Li, J.; Shen, G.N.; Li, W.L.; Gong, Y.X.; Mao, Y.Y.; Xie, D.P.; et al. Anti-inflammatory effect of hispidin on LPS induced macrophage inflammation through MAPK and JAK1/STAT3 signaling pathways. Appl. Biol. Chem. 2020, 63, 1–9. [CrossRef]
14. Park, J.M.; Lee, J.S.; Song, J.E.; Sim, Y.C.; Ha, S.J.; Hong, E.K. Cytoprotective effect of hispidin against palmitate-induced lipotoxicity in C2C12 myotubes. Molecules 2015, 20, 5456–5467. [CrossRef] [PubMed]
15. Maruta, H.; Tu, P.T.B.; Mok-Ryeon, A. Natural or Synthetic Anti-Melanogenic Compounds That Block the PDGFR-EGFR-PAK1-MITF-Tyrosinase Signaling Pathway. J. Dermatol. Res. Ther. 2017, 3, 48.
16. Gribble, G.W. Progress in the Chemistry of Organic Natural Products, 1st ed.; Springer: Berlin, Germany, 1996; pp. 1–423.
17. Chen, W.; He, F.Y.; Li, Y.Q. The apoptosis effect of hispolon from Phellinus linteus (Berkeley & Curtis) Teng on human epidermoid KB cells. J. Ethnopharmacol. 2006, 105, 280–285. [CrossRef] [PubMed]
18. Lee, Y.S.; Kang, Y.H.; Jung, J.Y.; Lee, S.; Ohuchi, K.; Shin, K.H.; Kang, I.J.; Park, J.H.; Shin, H.K.; Lim, S.S. Protein glycation inhibitors from the fruiting body of Phellinus linteus. Biol. Pharm. Bull. 2008, 31, 1968–1972. [CrossRef] [PubMed]
19. Halliwell, B.; Gutteridge, J.M. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J. 1984, 219, 1–14. [CrossRef] [PubMed]
20. Shao, H.J.; Jeong, J.B.; Kim, K.J.; Lee, S.H. Anti-inflammatory activity of mushroom-derived hispidin through blocking of NF-κB activation. J. Sci. Food Agric. 2015, 95, 2482–2486. [CrossRef] [PubMed]

21. Zhang, D.; Das, D.B.; Rielly, C.D. Microneedle assisted micro-particle delivery from gene guns: Experiments using skin-mimicking agarose gel. J. Pharm. Sci. 2014, 103, 613–627. [CrossRef] [PubMed]

22. Murray, P.R.; Jo, E.; Turnidge, B. Manual of Clinical Microbiology, 9th ed.; ASM Press: Washington, DC, USA, 2007; pp. 1152–1172.

23. Xu, B.; Zhu, D.; Yin, D.; Jin, Q.; Gao, S.; Zhao, J. Pyramid-Shaped Tips Based Polymer Microneedles for Transdermal Drug or Nanoparticle Delivery. In Proceedings of the 2007 7th IEEE Conference on Nanotechnology (IEEE NANO), Hong Kong, China, 2–5 August 2007; pp. 287–290.